Autumn Research Update Meeting 2025
Our 2025 Autumn Research Update Meeting will take place once again at the renowned Royal Society of Medicine (RSM), Wimpole Street, London, on Monday 10 November, where guests can look forward to an engaging agenda featuring the latest updates from our funded research. Theme: Revolutionising...
Learn more
Genetic manipulators of Alpha Synuclein
In the brains of people with Parkinson’s, there is an accumulation of alpha synuclein protein. It clusters and aggregates together forming dense circular objects inside neurons called Lewy bodies. This build up of alpha synuclein is believed to play a role in the neurodegeneration associated…
Accelerating Medicines Partnership for Parkinson’s – AMP-PD
The US National Institute of Health (NIH) have recently announced the opening of a vast new data portal for Parkinson’s research. It is part of the Accelerating Medicines Partnership for Parkinson’s, or AMP-PD initiative. AMP-PD is a huge collaborative effort between the NIH and multiple…
Ambroxol: Further validation for potential in Parkinson’s
Small variations in DNA are associated with approximately 1 in 5 of Parkinson’s cases. One of the most common genetic risk factors of developing Parkinson’s occurs in a region of DNA called the GBA gene. This gene provides the code for producing an enzyme – Glucocerebrosidase…
An exercise in expectations: Exenatide III
In August 2017, the results of a Phase II double-blind, placebo controlled clinical trial investigating whether the diabetes drug Exenatide (aka Bydureon) can be repurposed for the treatment of Parkinson’s were published. Despite the fact that the study did not meet most of its end points, the Parkinson’s community got very excited about one […]
Webinar – Dyskinesia in Parkinson’s
Presented by the Journal of Parkinson’s Disease, Cure Parkinson’s and Van Andel Institute. Chair Professor Patrik Brundin is joined by fellow panellists Professor Ray Chaudhuri from Kings College London, Professor Angela Cenci Nilsson from Lund University in Sweden with patient perspectives from Martin Taylor, founder…